Randomized Phase 2 Study Of IMC-A12 For HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment

News — By on November 20, 2008 at 10:00 am

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment. IMC-A12 is ImClone’s fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.

Please read the complete article and let us know what you think below.

Leave a Reply


Leave a Trackback